ArticleOman medical journal2025
Selective Immunoglobulin A Deficiency Among Omani Patients Screened for Celiac Disease: A Cross-sectional Study.
Article in Oman medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Selective immunoglobulin A deficiency (SIgAD) is characterized by an isolated deficiency of serum IgA while immunoglobulin G (IgG) and immunoglobulin M (IgM) levels remain normal. Symptoms range from asymptomatic to recurrent infections. We aimed to determine the prevalence of IgAD and SIgAD among Omani patients undergoing screening for celiac disease. Methods: This cross-sectional study included Omani nationals aged above one year, who were screened for celiac disease with anti-tissue transglutaminase (anti-tTG) IgA at Royal Hospital, Muscat, from January 2005 to December 2023. IgAD was defined as a total serum IgA level below the age-dependent reference range. SIgAD was diagnosed when both IgG and IgM values were within their respective reference limits. The prevalence of IgAD and SIgAD was statistically reviewed. Results: Of the 9615 individuals who underwent screening for celiac disease, 114 had low IgA levels. The prevalence of IgAD was 1.2%, and among these, 0.4% were confirmed to have SIgAD. The majority were > 14 years. Patients aged 6-14 years and > 14 years were more likely to have IgAD compared to 1-2 years old. Only 39 (34.2%) patients underwent further testing to confirm SIgAD, while the remaining 75 (65.8%) did not undergo follow-up IgG and IgM testing. Among the patients with confirmed SIgAD, 11 (28.2%) underwent further testing with anti-tTG IgG antibody, with only one (9.1%) testing positive for celiac disease as confirmed by esophagogastroduodenoscopy (EGD) and histopathology. Patients with anti-tTG IgG and EGD exhibited a significantly increased risk of low IgA levels. The remaining 28 (71.8%) patients did not undergo further celiac disease workup (anti-tTG IgG antibody, EGD, or genetic testing). Conclusions: IgAD was present in 1.2% of Omani patients evaluated for celiac disease, and 0.4% had confirmed SIgAD. Referral to an immunologist is recommended when IgG/IgM levels are low or infections are recurrent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.